AR046337A1 - Imidazopirazina inhibidoras de las tirosinquinasas - Google Patents
Imidazopirazina inhibidoras de las tirosinquinasasInfo
- Publication number
- AR046337A1 AR046337A1 ARP040103731A ARP040103731A AR046337A1 AR 046337 A1 AR046337 A1 AR 046337A1 AR P040103731 A ARP040103731 A AR P040103731A AR P040103731 A ARP040103731 A AR P040103731A AR 046337 A1 AR046337 A1 AR 046337A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- cycloalkenyl
- nr222r333
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
Abstract
Inhiben la enzima IGF-1R y son útiles para el tratamiento y/o la prevención de diferentes enfermedades y afecciones que responden al tratamiento por inhibición de tirosinquinasas. Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal del mismo aceptable para uso farmacéutico, en la cual Q1 es arilo1, heteroarilo1, cicloalquilo, heterociclilo, cicloalquenilo, o heterocicloalquenilo, cualquiera de los cuales está substituido opcionalmente con entre uno y cinco substituyentes G1 independientes; R1 es alquilo, cicloalquilo, bicicloalquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, heterociclilo, o heterobicicloalquilo, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes G11 independientes; G1 y G41 son independientemente halo, oxo, -CF3, -OCF3, -OR2, -NR2R3(R3a)j1, -C(O)R2, -CO2R, -CONRaR3, -NO2, -CN, -S(O)j1R2, -SO2NR2R3, NR2(C=O)R3, NR2(C=O)OR3, NR2(C=O)NR2R3, NR2S(O)j1R3, -(C=S)OR2, -(C=O)SR2, - NR2(C=NR3)NR2aR3a, -NR2(C=NR3)OR2a, -NR2(C=NR3)SR3a, -O(C=O)OR2, -O(C=O)NR2R3, -O(C=O)SR2, -S(C=O)OR2, -S(C=O)NR2R3, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10alquilo C1-10, alcoxi C1-10alquenilo C2-10, alcoxi C1-10alquinilo C2- 10, alquiltio C1-10alquilo C1-10, alquiltio C1-10alquenilo C2-10, alquiltio C1-10alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8alquilo C1-10, cicloalquenil C3-8alquilo C1-10, cicloalquil C3-8alquenilo C1-10, cicloalquenil C3-8alquenilo C2-10, cicloalquil C3-8alquinilo C2-10, cicloalquenil C3-8alquinilo C2-10, heterociclil-alquilo C0-10,heterociclil-alquenilo C2-10, o heterociclil-alquinilo C2-10, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes independientes halo, oxo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j1a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j1aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j1aR333, -(C=S)OR222, - (C=O)R222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, o -S(C=O)NR222R333; o -(X1)n-(Y1)m-R4; o aril-alquilo C0-10, aril-alquenilo C2-10, o aril-alquinilo C2- 10, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes independientes, -CF3, -OCF3, -OR222, -NR222R333(R333a)j2a, -C(O)R222, -CO2R222, -CONR222R333, -NO2, -CN, -S(O)j2aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j2aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, -O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, o -S(C=O)NR222R333; o hetaril- alquilo C0-10, hetaril-alquenilo C2-10, o hetaril-alquinilo C2-10, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes independientes halo, -CF3, -OCF3, -OR222, -NR222R333(R333a)j3a, -C(O)R222, -CO2R222, - CONR222R333, -NO2, -CN, -S(O)j3aR222, -SO2NR222R333, NR222(C=O)R333, NR222(C=O)OR333, NR222(C=O)NR222R333, NR222S(O)j3aR333, -(C=S)OR222, -(C=O)SR222, -NR222(C=NR333)NR222aR333a, -NR222(C=NR333)OR222a, -NR222(C=NR333)SR333a, -O(C=O)OR222, - O(C=O)NR222R333, -O(C=O)SR222, -S(C=O)OR222, o -S(C=O)NR222R333; G11 es halo, oxo, -CF3, -OCF3, -OR21, -NR21R31(R3a1)j4, -C(O)R21, -CO2R21, -CONR21R31, -NO2, -CN, -S(O)j4R21, -SO2NR21R31, NR21(C=O)R31, NR21(C=O)OR31, NR21(C=O)NR21R31, NR21S(O)j4R31, -(C=S)OR21, -(C=O)SR21, -NR21(C=NR31)NR2a1R3a1, -NR21(C=NR31)OR2a1, -NR21(C=NR31)SR3a1, -O(C=O)OR21, -O(C=O)NR21R31, -O(C=O)SR21, -S(C=O)OR21, -S(C=O)NR21R31, -P(O)OR21OR31, alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10alquilo C1-10, alcoxi C1-10alquenilo C2-10, alcoxi C1-10alquinilo C2-10, alquiltio C1-10alquilo C1-10, alquiltio C1-10alquenilo C2-10, alquiltio C1-10alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8alquilo C1-10, cicloalquenil C3-8alquilo C1-10, cicloalquil C3-8alquenilo C2-10, cicloalquenil C3-8alquenilo C2-10, cicloalquil C3-8alquinilo C2-10, cicloalquenil C3-8alquinilo C2-10, heterociclil-alquilo C0-10, heterociclil-alquenilo C2-10, o heterociclil-alquinilo C2-10, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes independientes halo, oxo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333a1)j4a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j4aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j4aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222a1R333a1, -NR2221(C=NR3331)OR222a1, -NR2221(C=NR3331)SR333a1, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, - P(O)OR2221OR3331, o -S(C=O)NR2221R3331; o aril-alquilo C0-10, aril-alquenilo C2-10, o aril-alquinilo C2-10, cualquiera de los cuales está substituido opcionalmente con uno o más substituyentes independientes halo, -CF3, -OCF3, -OR2221, - NR2221R3331(R333a1)j5a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j5aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j5aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222a1R333a1, - NR2221(C=NR3331)OR222a1, -NR2221(C=NR3331)SR333a1, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, o -S(C=O)NR2221R3331; o hetaril-alquilo C0-10, hetaril-alquenilo C2-10, o hetaril-alquinilo C2-10, cualquiera de los cuales está substituido opcionalmente con uno o más independientes halo, -CF3, -OCF3, -OR2221, -NR2221R3331(R333a1)j6a, -C(O)R2221, -CO2R2221, -CONR2221R3331, -NO2, -CN, -S(O)j6aR2221, -SO2NR2221R3331, NR2221(C=O)R3331, NR2221(C=O)OR3331, NR2221(C=O)NR2221R3331, NR2221S(O)j6aR3331, -(C=S)OR2221, -(C=O)SR2221, -NR2221(C=NR3331)NR222a1R333a1, -NR2221(C=NR3331)OR222a1, -NR2221(C=NR3331)SR333a1, -O(C=O)OR2221, -O(C=O)NR2221R3331, -O(C=O)SR2221, -S(C=O)OR2221, -P(O)OR2221OR3331, o - S(C=O)NR2221R3331; o G11 se toma junto con el carbono al cual está unido para formar una unión doble que está substituida con R5 y G111; R2, R2a, R3, R3a, R222, R222a, R333, R333a, R21, R2a1, R31, R3a1, R2221, R222a1, R3331, y R333a1 son cada uno independientemente igual a alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10alquilo C1-10, alcoxi C1-10alquenilo C2-10, alcoxi C1-10alquinilo C2-10, alquiltio C1-10alquilo C1-10, alquiltio C1-10alquenilo C2-10, alquiltio C1-10alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalquil C3-8alquilo C1-10, cicloalquenil C3-8alquilo C1-10, cicloalquil C3-8alquenilo C2-10, cicloalquenil C3-8alquenilo C2-10, cicloalquil C3-8alquinilo C2-10, cicloalquenil C3-8alquinilo C2-10, heterociclil-alquilo C0-10, heterociclil-alquenilo C2-10, o heterociclil-alquinilo C2-10, cualquiera de los cuales está opcionalmente substituido con uno o más substituyentes G111; o aril-alquilo C0-10, aril-alquenilo C2-10, o aril-alquinilo C2-10, hetaril-alquilo C0-10, hetaril-alquenilo C2-10, o hetaril-alquinilo C2-10, cada uno de los cuales está substituido opcionalmente con uno o más substituyentes G111; o en el caso de -NR2R3(R3a)j1 o -NR222R333(R333a)j1a o -NR222R333(R333a)j2a o - NR2221R3331(R333a1)j3a o -NR2221R3331(R333a1)j4a o -NR2221R3331(R333a1)j5a o -NR2221R3331(R333a1)j6a, R2 y R3 o R222 y R333 o R2221 y R3331 tomados junto con el nitrógeno al cual están unidos forman un anillo de 3-10 miembros cíclico saturado, cíclico no saturado, cíclico saturado heterocíclico, o cíclico no saturado heterocíclico, en donde dicho anillo está opcionalmente substituido con uno o más substituyentes G111; X1 e Y1 son, cada uno independientemente -O-, -NR7-, -S(O)J7-, -CR5R6-, -N(C(O)OR7)-, -N(C(O)R7)-, -N(SO2R7)-, -CH2O-, -CH2S-, -CH2N(R7)-, -CH(NR7)-, -CH2N(C(O)R7)-, -CH2N(C(O)OR7)-, -CH2N(SO2R7)-, -CH(NHR7)-, -CH(NHC(O)R7)-, -CH(NHSO2R7)-, -CH(NHC(O)OR7)-, -CH(OC(O)R7)-, -CH(OC(O)NHR7)-, -CH=CH-, -CsC-, -C(=NOR7)-, - C(O)-, -CH(OR7)-, -C(O)N(R7)-, -N(R7)C(O)-, -N(R7)S(O)-, -N(R7)S(O)2-, -OC(O)N(R7)-, -N(R7)C(O)N(R7)-, -NR7C(O)O-, -S(O)N(R7)-, -S(O)2N(R7)-, -N(C(O)R7)S(O)-, -N(C(O)R7)S(O)2-, -N(R7)S(O)N(R7)-, -N(R7)S(O)2N(R7)-, -C(O)N(R7)C(O)-, -S(O)N(R7)C(O)-, - S(O)2N(R7)C(O)-, -OS(O)N(R7)-, -OS(O)2N(R7)-, -N(R7)S(O)O-, -N(R7)S(O)2O-, -N(R7)S(O)C(O), -N(R7)S(O)2C(O)-, -SON(C(O)R7)-, -SO2N(C(O)R7)-, -N(R7)SON(R7)-, -N(R7)SO2N(R7)-, -C(O)O-, -N(R7)P(OR8)O-, -N(R7)P(OR8)-, -N(R7)P(O)(OR8)O-, -N(R7)P(O)(OR8)- , -N(C(O)R7)P(OR8)O-, -N(C(O)R7)P(OR8)-, -N(C(O)R7)P(O)(OR8)O-, -N(C(O)R7)P(OR8)-, -CH(R7)S(O)-,-CH(R7)S(O)2-, -CH(R7)N(C(O)OR7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(SO2R7), -CH(R7)O-, -CH(R7)S-, -CH(R7)N(R7)-, -CH(R7)N(C(O)R7)-, -CH(R7)N(C(O)OR7)-, - CH(R7)N(SO2R7)-, -CH(R7)C(=NOR7)-, -CH(R7)C(O)-, -CH(R7)CH(OR7)-, -CH(R7)C(O)N(R7)-, -CH(R7)N(R7)C(O)-, -CH(R7)N(R7)S(O)-, -CH(R7)N(R7)S(O)2-, -CH(R7)OC(O)N(R7)-, -CH(R7)N(R7)C(O)N(R7)-, -CH(R7)NR7C(O)O-, -CH(R7)S(O)N(R7)-, -CH(R7)S(O)2N(R7)-, - CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(C(O)R7)S(O)-, -CH(R7)N(R7)S(O)N(R7)-, -CH(R7)N(R7)S(O)2N(R7)-, -CH(R7)C(O)N(R7)C(O)-, -CH(R7)S(O)N(R7)C(O)-, -CH(R7)S(O)2N(R7)C(O)-, -CH(R7)OS(O)N(R7)-, -CH(R7)OS(O)2N(R7)-, -CH(R7)N(R7)S(O)O-, -CH(R7)N(R7)S(O)2O-, - CH(R7)N(R7)S(O)C(O)-, -CH(R7)N(R7)S(O)2C(O)-, -CH(R7)SON(C(O)R7)-, -CH(R7)SO2N(C(O)R7)-, -CH(R7)N(R7)SON(R7)-, -CH(R7)N(R7)SO2N(R7)-, -CH(R7)C(O)O-, -CH(R7)N(R7)P(OR8)O-, -CH(R7)N(R7)P(OR8)-, -CH(R7)N(R7)P(O)(OR8)O-, -CH(R7)N(R7)P(O)(OR8)-, - CH(R7)N(C(O)R7)P(OR8)O-, -CH(R7)N(C(O)R7)P(OR8)-, -CH(R7)N(C(O)R7)P(O)(OR8)O-, o -CH(R7)N(C(O)R7)P(OR8)-; o X1 y Y1 cada uno está representado por una de las fórmulas estructurales (2), (3), (4), (5), (6) ó (7); R10, tomado junto con la fosfinamida o fosfonamida, es un sistema anular arilo, heteroarilo o heterociclilo de 5, 6 o 7 miembros; R5, R6 y G111 son, cada uno independientemente alquilo C0-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-10alquilo C1-10, alcoxi C1-10alquenilo C2-10, alcoxi C1-10alquinilo C2-10, alquiltio C1-10alquilo C1-10, alquiltio C1-10alquenilo C2-10, alquiltio C1-10alquinilo C2-10, cicloalquilo C3-8, cicloalquenilo C3-8, cicloalq
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51171203P | 2003-10-15 | 2003-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046337A1 true AR046337A1 (es) | 2005-12-07 |
Family
ID=34465267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103731A AR046337A1 (es) | 2003-10-15 | 2004-10-14 | Imidazopirazina inhibidoras de las tirosinquinasas |
Country Status (19)
Country | Link |
---|---|
US (2) | US7459554B2 (es) |
EP (1) | EP1675860B1 (es) |
JP (1) | JP4916883B2 (es) |
KR (1) | KR100872204B1 (es) |
CN (1) | CN1898240B (es) |
AP (1) | AP2006003620A0 (es) |
AR (1) | AR046337A1 (es) |
AT (1) | ATE525377T1 (es) |
AU (1) | AU2004282219C1 (es) |
BR (1) | BRPI0415395A (es) |
CA (1) | CA2542481A1 (es) |
ES (1) | ES2372694T3 (es) |
IL (1) | IL174948A0 (es) |
NO (1) | NO20062136L (es) |
RU (1) | RU2405784C2 (es) |
SG (1) | SG132683A1 (es) |
TW (1) | TW200530238A (es) |
UA (1) | UA83509C2 (es) |
WO (1) | WO2005037836A2 (es) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1664042A1 (en) * | 2003-09-03 | 2006-06-07 | Galapagos N.V. | IMIDAZO 1,5-a PYRIDINE OR IMIDAZO 1,5-a PIPERIDINE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF MEDICAMENT AGAINST 5-HT2A RECEPTOR-RELATED DISORDERS |
CA2542481A1 (en) * | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazopyrazine tyrosine kinase inhibitors |
DK1740591T3 (da) | 2004-04-02 | 2009-10-26 | Osi Pharm Inc | Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
EP1926996B1 (en) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EA015463B1 (ru) * | 2005-11-17 | 2011-08-30 | Оси Фармасьютикалз, Инк. | КОНДЕНСИРОВАННОЕ БИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ - ИНГИБИТОР mTOR, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЕГО СОДЕРЖАЩАЯ, И СПОСОБ ЛЕЧЕНИЯ РАКА |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
TW200730529A (en) * | 2005-12-07 | 2007-08-16 | Osi Pharm Inc | Process to prepare substituted imidazopyrazine compounds |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
DE602007006010D1 (de) * | 2006-05-31 | 2010-06-02 | Galapagos Nv | Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten |
WO2008022060A2 (en) * | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
AU2008232762B2 (en) * | 2007-03-28 | 2013-09-19 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US8124759B2 (en) | 2007-05-09 | 2012-02-28 | Abbott Laboratories | Inhibitors of protein kinases |
ES2372559T3 (es) * | 2007-05-09 | 2012-01-23 | Abbott Laboratories | Compuestos heterocíclicos condensados como inhibidores de proteína quinasas. |
WO2008141140A1 (en) * | 2007-05-09 | 2008-11-20 | Abbott Laboratories | Condensed heterocyclic compounds as inhibitors of protein kinases |
WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
WO2009038012A1 (ja) * | 2007-09-18 | 2009-03-26 | Taisho Pharmaceutical Co., Ltd. | 複素環化合物 |
CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2008307634A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2009091939A1 (en) | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
US8557814B2 (en) * | 2008-03-19 | 2013-10-15 | OSI Pharmaceuticals, LLC | mTOR inhibitor salt forms |
ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
WO2010123792A1 (en) * | 2009-04-20 | 2010-10-28 | Osi Pharmaceuticals, Inc. | Preparation of c-pyrazine-methylamines |
EP2424368B1 (en) * | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
US20120220595A1 (en) | 2009-11-12 | 2012-08-30 | OSI Pharmaceuticals, LLC | Deuterated Tyrosine Kinase Inhibitors |
US9765037B2 (en) | 2010-01-28 | 2017-09-19 | University Of Washington Through Its Center For Commercialization | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases |
EP2528919B1 (en) * | 2010-01-28 | 2016-11-02 | University of Washington | Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases |
KR101661383B1 (ko) * | 2010-02-08 | 2016-09-29 | 머크 샤프 앤 도메 비.브이. | 8-메틸-1-페닐-이미다졸[1,5-a]피라진 화합물 |
WO2011109572A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AR080754A1 (es) * | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
US20130085161A1 (en) | 2010-06-17 | 2013-04-04 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
CN102947274A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
CN103492390A (zh) | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | 氟苯基双环杂芳基化合物 |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
MX2014000518A (es) | 2011-07-13 | 2014-05-30 | Pharmacyclics Inc | Inhibidores de la tirosina quinasa de bruton. |
PT3689878T (pt) * | 2011-07-19 | 2022-01-05 | Merck Sharp & Dohme | 4-imidazopiridazin-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
US9598416B2 (en) | 2011-12-15 | 2017-03-21 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9475815B2 (en) | 2012-02-23 | 2016-10-25 | Bayer Intelletual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US9296753B2 (en) | 2012-06-04 | 2016-03-29 | Pharmacyclics Llc | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
JP2015532287A (ja) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ire1の調節 |
MA38183A1 (fr) | 2012-11-15 | 2017-03-31 | Pharmacyclics Inc | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
TW201441234A (zh) * | 2013-01-23 | 2014-11-01 | Merck Sharp & Dohme | Btk抑制劑 |
US9834575B2 (en) | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
CA2913035C (en) | 2013-05-20 | 2017-08-01 | University Of Washington Through Its Center For Commercialization | 5-aminopyrazole-4-carboxamide inhibitors of cdpk1 |
US10800751B2 (en) * | 2013-08-23 | 2020-10-13 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
WO2015048689A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2015057992A1 (en) | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
KR20160093062A (ko) | 2013-12-05 | 2016-08-05 | 아세르타 파마. 비.브이. | Pi3k 억제제 및 btk 억제제의 치료적 조합 |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP3082811B1 (en) | 2013-12-20 | 2020-01-15 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
SG11201605417QA (en) * | 2014-02-03 | 2016-08-30 | Cadila Healthcare Ltd | Heterocyclic compounds |
US9842152B2 (en) | 2014-02-19 | 2017-12-12 | Snowflake Computing, Inc. | Transparent discovery of semi-structured data schema |
CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
AU2015300798A1 (en) | 2014-08-07 | 2017-02-02 | Pharmacyclics Llc | Novel formulations of a Bruton's tyrosine kinase inhibitor |
ES2900184T3 (es) | 2014-08-11 | 2022-03-16 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2 |
AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
US20170239351A1 (en) | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
US20170231995A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106652A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
MA50817B1 (fr) | 2015-07-02 | 2021-10-29 | Acerta Pharma Bv | Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
HUE052893T2 (hu) | 2016-01-13 | 2021-05-28 | Acerta Pharma Bv | Antifolát és BTK-gátló terápiás kombinációi |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
AU2017368331A1 (en) | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
SG10201912192RA (en) * | 2016-12-07 | 2020-02-27 | Beigene Ltd | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS |
CN106831789A (zh) * | 2016-12-21 | 2017-06-13 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN111704615B (zh) * | 2017-09-08 | 2023-02-17 | 百济神州有限公司 | 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 |
MX2020003862A (es) * | 2017-10-18 | 2020-08-13 | Incyte Corp | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). |
CN118005640A (zh) | 2018-01-29 | 2024-05-10 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
IL281025B1 (en) | 2018-08-29 | 2024-08-01 | Acerta Pharma B V | Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide |
CN110964016B (zh) | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
BR112021006907A2 (pt) * | 2018-10-11 | 2021-09-08 | Basf As | Compostos aromáticos e usos farmacêuticos destes |
AU2020243376A1 (en) * | 2019-03-15 | 2021-09-30 | Alterity Therapeutics Limited | Compounds for and methods of treating diseases |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN113620957B (zh) * | 2020-05-08 | 2022-04-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种胺甲基吡嗪类化合物的制备方法 |
US11155547B1 (en) | 2020-06-18 | 2021-10-26 | Alterity Therapeutics Limited | Compounds for and methods of treating diseases |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
CN114920745B (zh) * | 2022-03-28 | 2024-05-24 | 深圳海博为药业有限公司 | 一种咪唑并吡嗪类化合物及其作为igf1r抑制剂的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
DE69734149T2 (de) | 1996-03-15 | 2006-07-06 | Astrazeneca Ab | Cinoline derivate und verwendung als heilmittel |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
KR20020000223A (ko) * | 1999-05-14 | 2002-01-05 | 존 비. 랜디스 | 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법 |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
WO2002045653A2 (en) * | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
EP1349574A2 (en) * | 2001-01-09 | 2003-10-08 | MERCK PATENT GmbH | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
CN1507355A (zh) * | 2001-05-08 | 2004-06-23 | Ĭ��ר������˾ | 使用抗egfr抗体和抗激素剂的联合疗法 |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
US20030114467A1 (en) * | 2001-06-21 | 2003-06-19 | Shakespeare William C. | Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
ATE353650T1 (de) * | 2002-04-16 | 2007-03-15 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
KR20070074667A (ko) | 2003-03-12 | 2007-07-12 | 화이자 프로덕츠 인크. | 피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체 |
CA2542481A1 (en) * | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazopyrazine tyrosine kinase inhibitors |
JP2007514759A (ja) * | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
DK1740591T3 (da) * | 2004-04-02 | 2009-10-26 | Osi Pharm Inc | Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring |
NZ551431A (en) * | 2004-06-03 | 2010-04-30 | Hoffmann La Roche | Treatment with cisplatin and an EGFR-inhibitor |
US20080299113A1 (en) * | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
-
2004
- 2004-10-14 CA CA002542481A patent/CA2542481A1/en not_active Abandoned
- 2004-10-14 AP AP2006003620A patent/AP2006003620A0/xx unknown
- 2004-10-14 ES ES04795392T patent/ES2372694T3/es active Active
- 2004-10-14 WO PCT/US2004/034219 patent/WO2005037836A2/en active Application Filing
- 2004-10-14 US US10/965,182 patent/US7459554B2/en active Active
- 2004-10-14 UA UAA200605222A patent/UA83509C2/uk unknown
- 2004-10-14 CN CN2004800372564A patent/CN1898240B/zh not_active Expired - Fee Related
- 2004-10-14 RU RU2006116503/04A patent/RU2405784C2/ru not_active IP Right Cessation
- 2004-10-14 AU AU2004282219A patent/AU2004282219C1/en not_active Ceased
- 2004-10-14 BR BRPI0415395-2A patent/BRPI0415395A/pt not_active IP Right Cessation
- 2004-10-14 AR ARP040103731A patent/AR046337A1/es not_active Application Discontinuation
- 2004-10-14 AT AT04795392T patent/ATE525377T1/de not_active IP Right Cessation
- 2004-10-14 JP JP2006535379A patent/JP4916883B2/ja not_active Expired - Fee Related
- 2004-10-14 SG SG200703772-4A patent/SG132683A1/en unknown
- 2004-10-14 EP EP04795392A patent/EP1675860B1/en active Active
- 2004-10-14 KR KR1020067009419A patent/KR100872204B1/ko not_active IP Right Cessation
- 2004-10-14 TW TW093131193A patent/TW200530238A/zh unknown
-
2006
- 2006-04-11 IL IL174948A patent/IL174948A0/en unknown
- 2006-05-12 NO NO20062136A patent/NO20062136L/no not_active Application Discontinuation
-
2008
- 2008-07-18 US US12/175,801 patent/US20090181940A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005037836A2 (en) | 2005-04-28 |
BRPI0415395A (pt) | 2006-12-12 |
RU2006116503A (ru) | 2007-11-20 |
KR100872204B1 (ko) | 2008-12-09 |
ES2372694T3 (es) | 2012-01-25 |
US20080227788A9 (en) | 2008-09-18 |
US20060084654A1 (en) | 2006-04-20 |
NO20062136L (no) | 2006-06-26 |
AU2004282219B2 (en) | 2009-07-30 |
UA83509C2 (en) | 2008-07-25 |
CN1898240A (zh) | 2007-01-17 |
AU2004282219A1 (en) | 2005-04-28 |
EP1675860A2 (en) | 2006-07-05 |
JP4916883B2 (ja) | 2012-04-18 |
US7459554B2 (en) | 2008-12-02 |
EP1675860B1 (en) | 2011-09-21 |
CA2542481A1 (en) | 2005-04-28 |
CN1898240B (zh) | 2011-08-03 |
ATE525377T1 (de) | 2011-10-15 |
US20090181940A1 (en) | 2009-07-16 |
RU2405784C2 (ru) | 2010-12-10 |
IL174948A0 (en) | 2006-08-20 |
AU2004282219C1 (en) | 2009-12-17 |
AP2006003620A0 (en) | 2006-06-30 |
JP2007509060A (ja) | 2007-04-12 |
SG132683A1 (en) | 2007-06-28 |
WO2005037836A3 (en) | 2005-06-09 |
KR20060086987A (ko) | 2006-08-01 |
TW200530238A (en) | 2005-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046337A1 (es) | Imidazopirazina inhibidoras de las tirosinquinasas | |
AR053090A1 (es) | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos | |
ES2328833T3 (es) | Inhibidores de proteina quinasa heterobiciclicos con anillo 6,6-biciclico. | |
ES2687498T3 (es) | Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa | |
ES2635564T3 (es) | Profármaco de tenofovir y usos farmacéuticos del mismo | |
AR117490A1 (es) | Inhibidores de kif18a | |
AR095609A1 (es) | Compuestos de pirrolopiridina | |
AR035174A1 (es) | Compuesto derivado de beta-aminoacido, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para tratar o prevenir trastornos inflamatorios y enfermedades mediadas por mmp, tnf y agrecansa y combinaciones de los mismos | |
AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos | |
AR070224A1 (es) | Inhibidores de proteina quinasa y uso de los mismos | |
AR084070A1 (es) | Inhibidores del bromodominio y usos de los mismos | |
AR077239A1 (es) | Prodrogas de compuestos n-acidicos utiles en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y trastorno bipolar. | |
ES2233489T3 (es) | Utilizaciones y composiciones de esteres de nitrato para sedacion. | |
AR052772A1 (es) | Formas cristalinas y proceso para preparar compuestos de espiro-hidantoina | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
AR066972A1 (es) | Derivados azapeptidicos | |
AU2013249474A1 (en) | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators | |
AR124008A1 (es) | 1,4-diazepanonas bicíclicas y sus usos terapéuticos | |
AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
AR120029A1 (es) | Compuestos heterocíclicos | |
AR125866A1 (es) | Inhibidores de la interacción de menina-mll | |
AR096727A1 (es) | Derivados terapéuticamente activos de estratrien-tiazol | |
RU2004130295A (ru) | Малые молекулы-ингибиторы проникновения | |
AR107974A1 (es) | Análogos de nucleósidos alquinil como inhibidores de rinovirus humanos | |
BR112019006937A2 (pt) | Composição farmacêutica, composto, forma cristalina do composto, agentes para reduzir sulfato de indoxila no sangue, para prevenir ou tratar uma doença causada por um aumento de sulfato de indoxila no sangue, para retardar a transição para terapia desubstituição renal e para suprimir o agravamento da função renal remanescente em um paciente após transição para terapia de substituição renal, uso do composto, e, métodos para reduzir sulfato de indoxila no sangue e para prevenir ou tratar uma doença |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |